Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

Shares of Greenwich LifeSciences climbed after the company said its immunotherapy to prevent breast cancer recurrences showed a roughly 80% reduction in recurrence rate during a late-stage trial. The ...

In a phase III trial, pre-op MRI did not reduce locoregional recurrences or improve survival among women with early-stage ...

Greenwich LifeSciences (GLSI) announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01. A ...

Is omission of the sentinel lymph node biopsy safe in early breast cancer in patients treated with breast conserving therapy ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

RT consisted of a conventionally fractionated regimen, with the delivery of a total dose of 60 Gy in 6 weeks, in a once-daily schedule of 2 Gy per fraction for a total of 30 fractions. Patients were ...

Primary disease recurrence after renal transplantation accounts for 7–8% of graft losses Disease recurrence after paediatric renal transplantation can be associated with a high or low risk of graft ...

Patients with stage I or II hormone receptor-negative breast cancer do not benefit from preoperative breast MRI, according to ...

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly ...